Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients

Abstract

Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Therefore, interest has increased in targeted therapeutics for the treatment of cervical cancer. Cetuximab, a monoclonal antibody, binds specifically to the epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor and… (More)
DOI: 10.1007/s00404-010-1389-1

4 Figures and Tables

Topics

  • Presentations referencing similar topics